Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: MedImmune LLC Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

NCT00111579
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 36 Months
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
5
States / cities
Layton, Utah • Ogden, Utah • Pleasant Grove, Utah + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2008 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

NCT02013804
View directory record Official record
Conditions
Advanced Malignancies
Interventions
MEDI0680 (AMP-514)
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
New Haven, Connecticut • Detroit, Michigan • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma

NCT00659659
View directory record Official record
Conditions
Asthma
Interventions
MEDI-563, Placebo Comp., Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • Galveston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of MEDI4893

NCT02296320
View directory record Official record
Conditions
Staphylococcus Aureus Pneumonia
Interventions
MEDI4893, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 130 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Jul 23, 2026, 9:09 PM EDT
Terminated Phase 1 Interventional

Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

NCT01891981
View directory record Official record
Conditions
Leukemia
Interventions
Moxetumomab Pasudotox
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

NCT02900157
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
MEDI9090, Durvalumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

NCT00860067
View directory record Official record
Conditions
Healthy or Stable Underlying Chronic Medical Condition
Interventions
Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
18
States / cities
Sacramento, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2011 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

NCT00816400
View directory record Official record
Conditions
Cancer
Interventions
MEDI-575
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Denver, Colorado • Indianapolis, Indiana • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

NCT02549651
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
MEDI4736, tremelimumab, AZD9150
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
La Jolla, California • Baltimore, Maryland • Albuquerque, New Mexico + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus

NCT01283139
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Sifalimumab 200 mg, Sifalimumab 600 mg, Sifalimumab 1,200 mg, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
17
States / cities
La Jolla, California • Palm Desert, California • San Leandro, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Jul 23, 2026, 9:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Post Marking Study to Evaluate the Safety of FluMist in Children

NCT00569894
View directory record Official record
Conditions
Healthy
Interventions
FLuMist, TIV (Injection), Unvaccinated Control
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
24 Months to 59 Months
Enrollment
29,296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Jul 23, 2026, 9:09 PM EDT
Completed No phase listed Observational

Long-Term Follow-Up Study of Psoriasis Patients

NCT00131066
View directory record Official record
Conditions
Psoriasis
Interventions
Follow up from previous treatment with MEDI-507
Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
7
States / cities
Little Rock, Arkansas • Denver, Colorado • Alpharetta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2008 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 2 Interventional

MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

NCT00072930
View directory record Official record
Conditions
Prostate Cancer
Interventions
MEDI-522, Docetaxel + Prednisone* + Zoledronic Acid
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
36
States / cities
Hoover, Alabama • Springdale, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

NCT03336606
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Cell Cancer, Squamous, Carcinoma, Squamous Cell
Interventions
MEDI0562
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Not applicable Interventional

Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities

NCT00130143
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
Ethyol (Amifostine)
Drug
Lead sponsor
The Dale & Frances Hughes Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2003 – 2004
U.S. locations
1
States / cities
East Stroudsburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2005 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.

NCT02576548
View directory record Official record
Conditions
HER2 Expressing Breast or Gastric/Stomach Cancers
Interventions
MEDI4276
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Stanford, California • Sarasota, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Early Phase 1 Interventional

Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma

NCT01861340
View directory record Official record
Conditions
Myeloma
Interventions
Lenalidomide, Dexamethasone, and MEDI-551
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jul 23, 2026, 9:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

NCT02671435
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Monalizumab, Durvalumab, Cetuximab, mFOLFOX6, Bevacizumab
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

NCT02115815
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Placebo, RSV sF 20 mcg, MEDI7510 (20 mcg RSV sF), RSV sF 50 mcg, MEDI7510 (50 mcg RSV sF), RSV sF 80 mcg, MEDI7510 (80 mcg RSV sF)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
60 Years to 99 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors

NCT02318394
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
MEDI0562
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
La Jolla, California • Ann Arbor, Michigan • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.

NCT04019561
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Interventions
MEDI0382 high dose, Placebo for MEDI0382 high dose, MEDI0382 low dose, Placebo for MEDI0382 low dose
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Tucson, Arizona • Canoga Park, California • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NCT03794544
View directory record Official record
Conditions
Resectable, Early-stage, NSCLC
Interventions
Durvalumab, Oleclumab, Monalizumab, Danvatirsen
Drug · Combination Product
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 102 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
La Jolla, California • Fort Myers, Florida • Leesburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study To Evaluate the Safety of Bivalent Vaccine

NCT00325481
View directory record Official record
Conditions
Healthy
Interventions
FluMist
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2007 · Synced Jul 23, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

NCT04261075
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
IPH5201, durvalumab, oleclumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Huntersville, North Carolina • Providence, Rhode Island • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Jul 23, 2026, 9:09 PM EDT